A single-arm phase 2 study of abemaciclib in adult patients with recurrent grade 3 oligodendroglioma.

ABSTRACT:

Background

Novel treatments are needed for oligodendroglioma that has recurred following radiotherapy (RT) and chemotherapy. The cyclin D1-CDK4 axis is frequently dysregulated in oligodendroglioma. Abemaciclib is a selective CDK4/6 inhibitor that achieves pharmacologically relevant concentrations in brain tumor tissue.

Methods

We conducted a single-arm, phase 2 trial evaluating the efficacy of abemaciclib in patients with recurrent oligodendroglioma, isocitrate dehydrogenase (IDH)-mutant and 1p/19q-codeleted, WHO grade 3, following prior RT and ≥1 line of alkylating chemotherapy. Patients received abemaciclib 200 mg twice daily. The primary endpoint was progression-free survival at 6 months (PFS-6).

Results

Ten patients were enrolled. The most common treatment-related

SUBMITTER: Wills CA 

PROVIDER: S-EPMC11815343 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature